{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T06:42:20Z","timestamp":1694673740276},"reference-count":6,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T00:00:00Z","timestamp":1366070400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To examine the efficacy of long\u2010term administration of lanthanum carbonate, changes in serum <jats:styled-content style=\"fixed-case\"><jats:roman>Ca<\/jats:roman><\/jats:styled-content>, phosphate, whole parathyroid hormone (<jats:styled-content style=\"fixed-case\">wPTH<\/jats:styled-content>), and <jats:styled-content style=\"fixed-case\">ALP<\/jats:styled-content> were examined in 40 patients who were able to tolerate dosage of lanthanum carbonate over a continuous period of 24 months. Concurrently, concomitant administration of other phosphate binders, cinacalcet, vitamin <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>, etc., was also examined. After 24 months, serum phosphorus levels (<jats:styled-content style=\"fixed-case\">P<\/jats:styled-content> levels) had decreased to within management target of guidelines, from 6.16\u2009\u00b1\u20091.44\u2009mg\/dL to 5.58\u2009\u00b1\u20091.15\u2009mg\/dL, and this effect was maintained for 2 years. There were no changes in <jats:styled-content style=\"fixed-case\"><jats:roman>Ca<\/jats:roman><\/jats:styled-content> level. <jats:styled-content style=\"fixed-case\">wPTH<\/jats:styled-content> did not change significantly but tended to increase at 12 months. The dose of concomitantly administered calcium carbonate and sevelamer hydrochloride was reduced. The <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>\u2010lowering function of lanthanum carbonate still held steady at 24 months following the start of dosage. Because of the rising trend seen in <jats:styled-content style=\"fixed-case\">wPTH<\/jats:styled-content>, dose of cinacalcet and\/or vitamin <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content> need to be modulated. Reducing the number of concomitantly administered phosphate binder tablets was desirable from the standpoint of patient adherence.<\/jats:p>","DOI":"10.1111\/1744-9987.12042","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T09:41:25Z","timestamp":1366105285000},"page":"22-28","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Continuous Oral Administration of Lanthanum Carbonate over 24 months"],"prefix":"10.1111","volume":"17","author":[{"given":"Takashi","family":"Ishizu","sequence":"first","affiliation":[{"name":"Department of Nephrology Tsukuba Central Hospital  Ushiku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Nephrology Tsukuba Central Hospital  Ushiku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneaki","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Nephrology Tsukuba Central Hospital  Ushiku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Nephrology Tsukuba Central Hospital  Ushiku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Taru","sequence":"additional","affiliation":[{"name":"Department of Nephrology Tsukuba Central Hospital  Ushiku Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.87.7.e10"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2007.00540.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-9987.2010.00893.x"},{"key":"e_1_2_6_5_1","first-page":"110","article-title":"Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease","volume":"20","author":"Negi S","year":"2010","journal-title":"Clin Calcium"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.5414\/CNP63127"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12058"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T07:03:01Z","timestamp":1694588581000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":6,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1111\/1744-9987.12042"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12042","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}